Andlauer Healthcare Group Inc.

As of June 30, 2025, Andlauer Healthcare Group Inc. has 39.15M shares outstanding.

As of June 30, 2025, Andlauer Healthcare Group Inc. trades at a trailing price-to-earnings ratio of 30.18. The price-to-sales ratio is 3.13, and the price-to-book ratio stands at 2.27.

As of June 30, 2025, Andlauer Healthcare Group Inc. trades at an EV/EBITDA multiple of 13.32 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.70 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Andlauer Healthcare Group Inc. trades at an EV/FCF ratio of 14.24, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Andlauer Healthcare Group Inc. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.51, indicating elevated leverage, while an interest coverage ratio of 19.59 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Andlauer Healthcare Group Inc. posted a return on equity (ROE) of 7.65, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.43 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.03, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.98, useful for judging operating efficiency across full business cycles. Inventory turnover of 86.15 indicates how many times Andlauer Healthcare Group Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended June 30, 2025. That works out to an effective tax rate of 25.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on November 4, 2025, Andlauer Healthcare Group Inc.'s stock has gained approximately 33.77% over the past 52 weeks. The 50-day moving average sits at 38.11, while the 200-day moving average is 35.29.

Over the twelve months ended June 30, 2025, Andlauer Healthcare Group Inc. posted a gross margin of 22.94, reflecting its pricing power and cost economics. The operating margin of 13.99 and net profit margin of 10.37 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. The dividend payout ratio of 26.73 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.02, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.73, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Andlauer Healthcare Group Inc. shareholders.

As of June 30, 2025, Andlauer Healthcare Group Inc. has an Altman Z-Score of 8.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.